Abstract
Few FDA-approved options are available for the treatment of pediatric psychosis. Furthermore, minimal literature exists supporting the use of long-acting injectable antipsychotics (LAIAs) in the pediatric population. Most literature focuses on the use of LAIAs in the adult population.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the American Academy of Child & Adolescent Psychiatry
Paper Title
Journal
Date
